Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

Key Takeaway: ClaimsFiler has notified investors of a lead plaintiff deadline in a class action lawsuit against uniQure N.V. for losses incurred between September and October 2025. Investors are encouraged to file claims as uniQure is accused of failing to disclose critical information regarding their drug AMT-130. This revelation led to a dramatic drop in share price by over 49% in November 2025, following the disclosure that the FDA questioned the adequacy of data for a Biologics License Application. The case is currently pending in the Southern District of New York.

Market Sentiment Analysis

CONCERNS & RISKS

  • uniQure investors are facing a securities class action lawsuit due to alleged failure to disclose material information.
  • The price of uniQure's shares dropped significantly, losing over 49% in value following negative news about their drug candidate AMT-130.

Full Press Release Details

NEW ORLEANS, April 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
uniQure investors should visit us at https://claimsfiler.com/cases/nasdaq-qure/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s planned Biologics License Application (“BLA”) submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that “the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission” and as a result, “the timing of the BLA submission for AMT-130 is now unclear.”
On this news, the price of uniQure’s shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.
The case is Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file claims against uniQure?

Investors must file lead plaintiff applications by April 13, 2026.

What period does the uniQure class action cover?

The class action covers purchases made from September 24 to October 31, 2025.

What caused uniQure's stock price to drop?

The stock plummeted after the FDA questioned the data for AMT-130's approval.

How much did uniQure shares fall on November 3, 2025?

Shares fell more than 49%, from $67.69 to $34.29.

Where can investors get more information about claims?

Investors can visit https://claimsfiler.com/cases/nasdaq-qure/ for details.

Last updated: Apr 9, 2026